Early and mid-term outcome of patients with low-flow–low-gradient aortic stenosis treated with newer-generation transcatheter aortic valves

Chiara Fraccaro¹, Giuseppe Tarantini¹**, Stefano Rosato², Giovanni Baglio³, Fausto Biancari⁴, Marco Barbanti⁶, Corrado Tamburino⁶, Francesco Bedogni⁷, Marco Ranucci⁸, Gian Paolo Ussia⁹, Fulvia Seccareccia⁴ and Paola D’Errigo² on behalf of the OBSERVANT II Research Group

Patients with non-paradoxical low-flow–low-gradient (LFLG) aortic stenosis (AS) are at increased surgical risk, and thus, they may particularly benefit from transcatheter aortic valve replacement (TAVR). However, data on this issue are still limited and based on the results with older-generation transcatheter heart valves (THVs). The aim of this study was to investigate early and mid-term outcome of TAVR with newer-generation THVs in the setting of LFLG AS. Data for the present analysis were gathered from the OBSERVANT II dataset, a national Italian observational, prospective, multicenter cohort study that enrolled 2,989 consecutive AS patients who underwent TAVR at 30 Italian centers between December 2016 and September 2018, using newer-generation THVs. Overall, 420 patients with LVEF ≤50% and mean aortic gradient ≤40 mmHg were included in this analysis. The primary outcomes were 1-year all-cause mortality and a combined endpoint including all-cause mortality and hospital readmission due to congestive heart failure (CHF) at 1 year. A risk-adjusted analysis was performed to compare the outcome of LFLG AS patients treated with TAVR (n = 389) with those who underwent surgical aortic valve replacement (SAVR, n = 401) from the OBSERVANT I study. Patients with LFLG AS undergoing TAVR were old (mean age, 80.8 ± 6.7 years) and with increased operative risk (mean EuroSCORE II, 11.5 ± 10.2%). VARC-3 device success was 83.3% with 7.6% of moderate/severe paravalvular leak. Thirty-day mortality was 3.1%. One-year all-cause mortality was 17.4%, and
the composite endpoint was 34.8%. Chronic obstructive pulmonary disease (HR 1.78) and EuroSCORE II (HR 1.02) were independent predictors of 1-year mortality, while diabetes (HR 1.53) and class NYHA IV (HR 2.38) were independent predictors of 1-year mortality or CHF. Compared with LFLG AS treated with SAVR, TAVR patients had a higher rate of major vascular complications and permanent pacemaker, while SAVR patients underwent more frequently to blood transfusion, cardiogenic shock, AKI, and MI. However, 30-day and 1-year outcomes were similar between groups. Patients with non-paradoxical LFLG AS treated by TAVR were older and with higher surgical risk compared with SAVR patients. Notwithstanding, TAVR was safe and effective with a similar outcome to SAVR at both early and mid-term.

**KEYWORDS**
low-flow–low-gradient, aortic stenosis, transcatheter aortic valve replacement, valvular heart disease, left ventricular dysfunction

### Introduction

Transcatheter aortic valve replacement (TAVR) is as effective and safe as surgical aortic valve replacement (SAVR), and it has become the first-choice therapy in increased risk patients with severe aortic stenosis (AS) as well as otherwise lower-risk elderly (1). LFLG AS is present in about 5% to 10% of patients with or without ischemic cardiomyopathy (2). Left ventricular impairment is reversible after valve replacement when due to afterload mismatch or partially reversible when cardiomyopathy or myocardial fibrosis subsided. The treatment of these patients is challenging, and SAVR entails an increased operative mortality ranging from 6 to 30% (3–9). TAVR seems to be promising in this setting because of its increasing procedural safety (short operative time and no need for extracorporeal circulation with consequent better myocardial protection), as well as hemodynamic performance of transcatheter devices (10). However, TAVR downsides remain, such as post-procedural paravalvular leak (PVL) and need for permanent pacemaker (PPM), that might be detrimental in the setting of an already impaired LVEF (11, 12). To date, evidence supporting the value of TAVR in this setting is lacking (13–16).

In the last decade, the Italian Ministry of Health promoted the monitoring throughout the country of data regarding the treatments and outcomes of all patients affected by severe AS, which were collected into two national datasets: OBSERVANT I and OBSERVANT II. The primary aim of this study was to assess, in the large national study OBSERVANT II, the early and mid-term outcome of TAVR performed with newer-generation THVs in the setting of LFLG AS. Moreover, the secondary aim was to compare the outcome of these patients with that of patients who underwent SAVR included in the OBSERVANT I study (17).

### Materials and methods

#### Data source

Data for this analysis were gathered from the OBSERVANT II datasets. OBSERVANT II was a national observational, prospective, multicenter cohort study that enrolled 2,989 consecutive AS patients who underwent TAVR at 30 Italian centers of cardiology between December 2016 and September 2018 (18–20). Twenty-eight centers met the data quality criteria required by the study protocol, and their data were included in the present analysis. The study protocol was approved by local ethics committees, and the recruited patients gave their consent to participate in this study. Data on baseline characteristics, operative details, and adverse events occurred during the index hospitalization were prospectively collected in an electronic case report form. Data on adverse events occurred after hospital discharge were gathered by a linkage with the National Hospital Discharged Records database provided by the Italian Ministry of Health and other administrative databases available through a collaboration with the Italian National Program for Outcome Evaluation (PNE-AGENAS). Linking to these national registries guaranteed complete follow-up data on outcomes at 1-year follow-up. For the secondary analysis, aimed at comparing outcomes between TAVR and SAVR patients, the SAVR historical cohort was obtained from the OBSERVANT I dataset that enrolled 7,618 consecutive AS patients who underwent TAVR (1,911 patients) or SAVR (5,707 patients) at 93 Italian centers between December 2010 and June 2012 (21).

#### Study population

Out of the 2,989 patients who underwent TAVR for severe AS and included in the OBSERVANT II dataset, 420 patients...
met the following inclusion criteria of this analysis: (1) left ventricular ejection fraction (LVEF) ≤50% and (2) mean aortic transvalvular gradient <40 mmHg. Only those patients receiving new-generation THVs (Acurate, Boston Scientific, MA, USA; Evolut R and PRO, Medtronic, Minneapolis, MN, USA; Lotus, Boston Scientific, Marlborough, MA, USA; Portico, Abbott Vascular, Santa Clara, CA, USA; Sapient 3, Edwards Lifesciences Corp., Irvine, CA, USA; Engager, Medtronic 3F Therapeutics, Santa Ana, CA, USA) were included in this study. Active endocarditis was an exclusion criterion. Furthermore, LFLG TAVR patients (n = 389) from the OBSERVANT II dataset were compared with patients who underwent SAVR from the OBSERVANT I dataset (n = 401) (21). Active endocarditis, porcelain aorta, hostile chest, emergency procedure, and grade 3 of frailty based on the geriatric status scale (GSS) index (22) were exclusion criteria for this sub-analysis (Figure 1).

Outcomes

The primary outcomes were 1-year all-cause mortality and the composite of mortality and hospital readmission due to congestive heart failure (CHF) at 1 year (this endpoint has been adopted as a surrogate of futility). The secondary outcomes were 30-day mortality and the following adverse events occurring during the index hospitalization: stroke, conversion to cardiac surgery, complication at the left ventricular apex, major vascular injury, acute kidney injury, post-operative change in estimated glomerular filtration rate (e-GFR), myocardial infarction (MI), permanent pacemaker (PPM) implantation, cardiogenic shock, infections, red blood cell transfusion, procedure for cardiac tamponade, as well as valve prosthesis performance defined as the mean and peak post-procedural transvalvular gradient and paravalvular regurgitation. Major vascular injury was
TABLE 1 Baseline characteristics of patients with LFLG AS included in OBSERVANT II dataset.

| Variables                                      | Total cohort (n = 420) | Missing |
|------------------------------------------------|------------------------|---------|
| Age, years                                     | 0 80.8 ± 6.7           |         |
| Female sex                                     | 0 147 (35.0)           |         |
| BMI, kg/m²                                      | 3 25.8 ± 4.4           |         |
| Diabetes                                       | 1 135 (32.2)           |         |
| Coronary artery disease                        | 3 150 (36.0)           |         |
| 1 Vessel                                       | 74 (17.7)              |         |
| 2 Vessels                                      | 27 (6.5)               |         |
| 3 Vessels/LM                                   | 49 (11.8)              |         |
| Previous myocardial infarction                 | 2 13 (3.1)             |         |
| <90 days                                       | 100 (23.8)             |         |
| >90 days                                       | 95 (22.7)              |         |
| Previous PCI                                   | 1 81 (19.3)            |         |
| Previous cardiac surgery                       | 0 203 (48.3)           |         |
| Previous CABG                                  | 0 106 (25.2)           |         |
| Previous aortic surgery                        | 1 19 (4.5)             |         |
| Other prior cardiac surgery procedures         | 0 37 (8.8)             |         |
| COPD                                           | 0 81 (19.3)            |         |
| Oxygen therapy                                 | 3 16 (3.8)             |         |
| e-GFR (ml/min/1.73 m²)                         | 1 108 (25.8)           |         |
| ≥45–60                                         |                       |         |
| ≥30–45                                         | 109 (26.0)             |         |
| ≥15–30                                         | 30 (7.2)               |         |
| <15                                            | 18 (4.3)               |         |
| Dialysis                                       | 1 18 (4.3)             |         |
| Neurological dysfunction                       | 0 8 (1.9)              |         |
| Porcelain aorta                               | 5 22 (5.3)             |         |
| Hostile chest                                  | 10 6 (1.5)             |         |
| Peripheral artery disease                      | 3 103 (24.7)           |         |
| Liver disease                                  | 2 4 (1.0)              |         |
| Pulmonary hypertension                         | 0 34 (8.1)             |         |
| Active cancer                                  | 2 16 (3.8)             |         |
| EuroSCORE II, %                                | 9 11.5 ± 10.2          |         |
| EuroSCORE II >4 %                              | 9 347 (84.4)           |         |
| Frailty classes                                | 0 228 (54.3)           |         |
| 0                                              | 98 (23.3)              |         |
| 1                                              | 87 (20.7)              |         |
| 2                                              | 7 (1.7)                |         |
| 3                                              | 16 (3.8)               |         |
| Critical preoperative status                   | 0 16 (3.8)             |         |
| NYHA classes                                   | 3 2 (0.5)              |         |
| I                                              | 82 (19.7)              |         |
| II                                             | 293 (70.3)             |         |
| III                                            | 40 (9.6)               |         |
| IV                                             |                       |         |

(Continued)

TABLE 1 (Continued)

| Variables                                      | Total cohort (n = 420) | Missing |
|------------------------------------------------|------------------------|---------|
| Unstable angina                                | 0 29 (6.9)             |         |
| Hemoglobin level, gr/dl                        | 6 11.9 ± 1.7           |         |
| Albumin level, gr/l                            | 126 3.9 ± 0.7          |         |
| AVA, cm²                                       | 21 0.7 ± 0.2           |         |
| AV pick gradient, mmHg                         | 18 50.2 ± 13.5         |         |
| AV mean gradient, mmHg                         | 0 29.6 ± 7.7           |         |
| AV annulus diameter, mm                        | 227 23.3 ± 2.5         |         |
| Mitral regurgitation                           | 1 33 (8.5)             |         |
| No/trivial                                     | 180 (46.6)             |         |
| Mild                                           | 162 (42.0)             |         |
| Moderate                                       | 44 (11.4)              |         |
| Severe                                         | 352 (83.8)             |         |
| ≤30%–50%                                       | 68 (16.2)              |         |

Continuous variables are reported as mean and standard deviation. Categorical variables are reported as counts and percentages (in parentheses).

AV, aortic valve; AVA, aortic valve area; BMI, body mass index; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; e-GFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PCI, percutaneous coronary intervention.

defined as any vascular complication at peripheral access site requiring surgical or endovascular intervention. Infectious complications were defined as clinically proven surgical site infections, infections involving organs, and sepsis. Technical success, device success, and early safety were reported according to VARC-3 definitions. Moreover, the major adverse cardiac and cerebrovascular event (MACCE) was considered as a primary outcome of interest for the comparison between TAVR and SAVR groups. MACCE was defined as a composite of all-cause mortality, stroke, myocardial infarction, and/or coronary revascularization.

Statistical analysis

Continuous variables were reported as means and standard deviations. Categorical variables were reported as counts and percentages. Missing data were not replaced. Differences between TAVR and SAVR groups were evaluated by the χ² or Fisher exact test for categorical variables and by the t-test for continuous variables. Multivariate Cox proportional hazards regression models were used to identify independent predictors of 1-year mortality and 1-year composite endpoint of mortality and hospital readmission due to CHF in the TAVR population. Moreover, for the secondary aim multivariate Cox regression models were used to compare
Early outcome after TAVR for LFLG AS

Most of the procedures were performed through a transfemoral approach (87%) using a self-expandable THV. The proportions of employed THVs are summarized in Figure 2. The rates of aortic valve pre- and post-dilatation were 31 and 18%, respectively. Mechanical circulatory support was needed in 1.4% of cases. Technical success was observed in 92% of cases. The device success rate at 30 days was 83% and early safety 68%. The mean transvalvular gradient significantly decreased from 29 mmHg to 8 mmHg ($p < 0.001$). Thirty-day mortality was 3.1%. Other early outcomes are summarized in Table 2.

One-year outcome after TAVR for LFLG AS

One-year follow-up was complete in all patients. One-year all-cause mortality was 17.4%. The rate of hospital readmission due to CHF was 24.3%, and the rate of composite outcome was 34.8%. Kaplan–Meyer estimates of 1-year all-cause mortality and of combined all-cause mortality or CHF are shown in Table 2.
Figure 3. Predictors of 1-year mortality were chronic obstructive pulmonary disease and EuroSCORE II (Table 3). Predictors of combined 1-year composite outcome were diabetes and NYHA class IV before intervention (Table 4). The type of THV was not selected in the stepwise model for any of the considered outcomes, and even forcing that variable into the models, it did not reach any statistical significance.

Outcome after SAVR or TAVR for LFLG AS

Four-hundred and one patients underwent SAVR, and 389 patients underwent TAVR. SAVR patients were younger, less frail, and symptomatic, with a less impaired LV function which resulted in a lower EuroSCORE II (Supplementary Table 1). Still SAVR patients had a higher prevalence of CAD requiring concomitant CABG. Despite such differences, the unadjusted rates of 30-day mortality (SAVR, 4.5% TAVR, 3.3%, \( p = 0.407 \)) and stroke (SAVR, 1.3%; TAVR 1.8%, \( p = 0.540 \)) were similar between groups. However, SAVR patients required more frequently blood transfusion and suffered AKI, MI, and cardiogenic shock requiring longer intensive care unit stay; TAVR had a higher rate of major vascular complications, need for permanent pacemaker and residual PVL (Table 5). The reduction in post-procedural mean transvalvular gradient was lower in SAVR patients compared with TAVR patients (Figure 4). At 1 year, all-cause death was 14.0% after SAVR and 16.7% after TAVR (\( p = 0.284 \)). About one-third of patients have died or required hospitalization for CHF, without significant difference between groups (33.2% after SAVR and 34.4% after TAVR; \( p = 0.704 \)). An adjusted Cox proportional hazards analysis showed that survival, freedom from death or rehospitalization due to CHF; and freedom from MACCE were similar after SAVR and TAVR (Figure 5). The IPTW analysis (Supplementary Figures 1–5) confirmed the results observed with the adjusted Cox proportional hazards analysis.

Discussion

The main findings of this study including a large series of patients with non-paradoxical LFLG AS treated with the last-generation THVs can be summarized as follows: (1) TAVR appears to be a safe treatment strategy in this high-risk population, with a 30-day mortality rate lower than that expected by an estimated operative risk; (2) one-third of the patients experienced death and/or rehospitalization due to CHF during the first year; and (3) TAVR-treated patients were older, more frail, and with a higher surgical risk compared with SAVR-treated patients. Notwithstanding, TAVR was as safe and effective as SAVR at early and mid-term (Figure 6, Central Illustration).

To the best of our knowledge, this is the largest series evaluating the outcome of TAVR performed with modern THVs devices in patients with LFLG AS. The risk profile of our study population was similar to that of the 287 patients with LFLG AS undergoing TAVR with similar devices included in the TOPAS trial (16). In that registry, Ribeiro et al. observed a favorable early outcome of TAVR in their high-risk cohort, with mortality rates of 3.8 and 20.1% at 30 days and 1 year, respectively, which are similar to the results of this study (3.1 and 17.4%, respectively). The minimally invasive nature of TAVR that avoids the use of extracorporeal circulation and the risk of myocardial injury, the prevalent transfemoral approach, and better hemodynamic performance and low delivery profile of most recent THVs, as well as increasing experience, might have contributed to these results. Indeed, prior series including older-generation devices reported less favorable results. In fact, in the GARY registry (14), hospital mortality was 7.8% and 1-year mortality was 32.2% among LFLG AS patients treated with TAVR.

However, about one-third of our population still may die or have a recurrence of CHF within the first year after TAVR. These findings are similar to the figures observed in the TOPAS trial (16). Similarly, a poor outcome was observed in 33% of patients in the PARTNER trial (24), whereas the rate of death, stroke, or rehospitalization was 27% in the PARTNER 2A trial.
FIGURE 3
Kaplan–Meyer estimates of survival (A) and freedom from all-cause mortality and/or rehospitalization due to congestive heart failure (CHF) (B).
(25) and 17% in the SURTAVI trial (26). This raises the question of the need to assess the potential futility in patients undergoing TAVR. Clinical futility means the lack of clinical benefit within the first year after treatment, and it has been variably defined

**TABLE 3** Independent predictors of 1-year mortality in LFLG AS treated with new-generation THV.

| Clinical variables       | HR  | P-value | CI 95% |
|-------------------------|-----|---------|--------|
| Age, years              | 1.00| 0.873   | 0.97   |
| Female sex              | 0.68| 0.167   | 0.40   |
| Porcelain aorta         | 1.84| 0.016   | 0.78   |
| Hostile chest           | 2.75| 0.036   | 0.75   |
| COPD                    | 1.78| 0.036   | 1.04   |
| Previous PCI            | 0.53| 0.052   | 0.28   |
| Concomitant PCI         | 0.50| 0.178   | 0.19   |
| e-GFR                   | 0.99| 0.022   | 1.00   |
| EuroSCORE II            | 1.02| 0.021   | 1.00   |
| Mean aortic transvalvular gradient | 0.98| 0.189   | 0.95   |

COPD, chronic obstructive pulmonary disease; e-GFR, estimated glomerular filtration rate; PCI, percutaneous coronary intervention; THV, transcatheter heart valve.

**TABLE 4** Independent predictors of combined 1-year mortality and rehospitalization due to congestive heart failure in LFLG AS treated with new-generation THV.

| Clinical variables       | HR  | P-value | CI 95% |
|-------------------------|-----|---------|--------|
| Age, years              | 1.00| 0.763   | 0.98   |
| Female sex              | 0.80| 0.023   | 0.55   |
| COPD                    | 1.41| 0.078   | 0.96   |
| Neurological dysfunction| 1.73| 0.286   | 0.63   |
| Previous PCI            | 1.64| 0.137   | 0.86   |
| Previous aortic surgery | 1.53| 0.103   | 1.09   |
| NYHA classes I and II   | Ref |         |        |
| NYHA class III          | 0.92| 0.685   | 0.60   |
| NYHA class IV           | 2.38| 0.002   | 1.36   |

CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; NYHA, New York Heart Association.

**TABLE 5** Early outcome of patients with LFLG AS treated with TAVR or SAVR.

| Outcomes                  | SAVR, n = 401 | TAVR, n = 389 | p-value |
|---------------------------|---------------|---------------|---------|
| 30-Day death              | Missing       | Missing       | 0.407   |
| Valve migration           | 0             | 2             | 0.007   |
| Myocardial infarction     | 3             | 0             | 0.036   |
| Major vascular complications | 25         | 0             | 0.022   |
| Permanent pacemaker       | 4             | 0             | <0.001  |
| Stroke                    | 5             | 0             | 0.540   |
| Cardiogenic shock         | 5             | 2             | <0.001  |
| Blood transfusion         | 25            | 2             | <0.001  |
| Transfused RBC units      | 0             | 0.2 ± 0.8     | <0.001  |
| AKI                       | 11            | 11            | <0.001  |
| PCI                       | 3             | 0             | 0.323   |
| Tamponade                 | 4             | 0             | 0.319   |
| Requiring surgery         | 6 (1.5)       | 2 (0.5)       |         |
| Requiring percutaneous treatment | 1 (0.3) | 2 (0.5) | |
| Infectious complications  | 11            | 0             | 0.148   |
| PVL                       | 37            | 0             | <0.001  |
| No/trivial                | 326 (89.6)    | 217 (55.8)    |         |
| Mild                      | 32 (8.8)      | 144 (37.0)    |         |
| Moderate                  | 4 (1.1)       | 25 (6.4)      |         |
| Severe                    | 2 (0.6)       | 3 (0.8)       |         |
| AV pick gradient, mmHg    | 91            | 22            | <0.001  |
| AV mean gradient, mmHg    | 95            | 7             | <0.001  |
| Intensive care unit stay, days | 7          | 7             | <0.001  |

Continuous variables are reported as mean and standard deviation. Categorical variables are reported as counts and percentages (in parentheses).

AKI, acute kidney injury; AV, aortic valve; PCI, percutaneous coronary intervention; PVL, paravalvular leak; RBC, red blood cells; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.
as the composite of death, rehospitalization due to CHF, or lack in functional recovery and improvement in quality of life (27). We observed that COPD and EuroSCORE II were independent predictors of 1-year mortality after TAVR and that diabetes and NYHA class IV symptoms independently predicted 1-year death and/or rehospitalization due to CHF. Low baseline mean gradient, anemia, renal failure, and the presence of moderate or severe post-procedural PVL after TAVR have been identified as other predictors of poor outcome in these patients (16, 28–30). However, a validated risk assessment tool for potential futility of TAVR is still lacking and the identification of patients who may not fully benefit from TAVR remains a dilemma for the heart team during the decision-making process.

When compared with an historical series of LFLG AS patients who underwent SAVR, TAVR patients included in the OBSERVANT II study were older, at a higher surgical risk, more fragile, with more comorbidities, and at an advanced stage of disease. Notwithstanding, 30-day mortality and stroke were similar between the two cohorts. Looking at post-procedural mean transvalvular gradient, THVs performed better than surgical aortic valve prostheses. This superiority of THVs is well-known, in particular with the use of supra-annular devices (60.8% in our series) (31–33). This is a point in favor of TAVR when discussing the best therapeutic option in the case of LFLG AS, as the more complete is the relief of afterload mismatch, the higher is the probability of LV recovery (34, 35). On the contrary, THVs still suffer from a higher rate of PVL and conduction disorders needing PPM implantation. The impact of PVL and PPM on clinical outcome and LV recovery after TAVR is still a matter of debate, and the scientific evidence on this field are controversial. Previous reports suggested that mild PVL is commonly observed after TAVR and usually leads to a benign outcome (36). However, a meta-analysis of 45 studies including around 13,000 patients concluded that moderate or greater post-TAVR PVL was associated with a more than 2-fold increase in overall all-cause mortality (37). Moreover, conduction disorders and PPM leading to cardiac dyssynchrony can be badly tolerated by an already impaired LVEF, as suggested by Weber et al. (11).

Beyond these differences, at risk-adjusted analysis for other confounding factors, we found that 1-year clinical outcome was similar between TAVR and SAVR patients. The same finding was reported by a sub-analysis of the PARTNER trial, where, after a small early hazard associated with SAVR in the first 30 days, both TAVR and SAVR similarly improved outcome with respect to medical therapy alone (13). These results have been further confirmed by a recent meta-analysis, showing that aortic valve replacement was associated with a significant decrease in all-cause mortality regardless of surgical or transcatheter approach and in all subclasses of LG AS (38).

There are some study limitations that deserve to be acknowledged. First, this is a prospective registry without an external event adjudication committee and echocardiographic...
Adjusted proportional hazards estimates of outcomes after TAVR and SAVR. (A) Survival; (B) Survival freedom from the composite of mortality and hospital rehospitalization due to CHF; (C) Survival freedom from MACCE (all-cause mortality, stroke, myocardial infarction, and coronary revascularization); COPD, chronic obstructive pulmonary disease; e-GFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.

Data were site-reported without analysis in a centralized core laboratory. Second, no data were available on either Agatston calcium score or contractile reserve evaluated by low-dose dobutamine echocardiography. However, recent evidence suggest no impact of contractile reserve on outcome after TAVR (39). Third, frailty was estimated through a simple toolset (Geriatric Status Scale) including only basic daily life activities and cognitive impairment; however, other variables relative to nutritional status (BMI, albumin, hemoglobin) were collected separately. Data about futility are underreported with respect to VARC-3 definition (23), as we included only death and rehospitalization due to CHF; while data about quality of life at follow-up are lacking. Moreover, we do not know the reasons for death (cardiac or not cardiac) at follow-up. Additionally, TAVR and SAVR cohorts are from different time periods (2010–2012 for SAVR group and 2016–2018 for TAVR group), thus potentially reflecting different patient’s selection and decision-making process by the local heart teams. However, as a matter of fact, no major changes in surgical techniques and technologies have been introduced during that time frame. Accordingly, we
would not expect a significant variation in the results if a more contemporaneous surgical series had been available. Finally, both OBSERVANT I and OBSERVANT II are multicenter studies, and thus, the “center effect” should theoretically be considered. However, the small number of patients per center fulfilling inclusion criteria for this sub-analysis does not allow considering the variable “center” in the models, which would become highly unstable from the statistical point of view.

In conclusion, in patients with non-paradoxical LFLG AS, TAVR was as safe and effective as SAVR at early and mid-term intervals. TAVR was associated with a lower risk of severe early adverse events and therefore might be of benefit over SAVR in elderly with non-paradoxical LFLG AS. Attention should be paid to procedural planning to optimize hemodynamic acute result and reduce the risk of PVL and PPM. The risk of futility is impending, and predictors of poor outcome are still a matter of debate. Further studies are needed to address these issues and improve patients’ selection.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by Segreteria del Comitato Etico per la Sperimentazione Clinica della Provincia di Padova, U.O.S.D. The patients/participants provided their written informed consent to participate in this study.

Author contributions

CF, GT, and FS contributed to conception and design of the study. SR organized the database. PD’E performed the statistical analysis. CF wrote the first draft of the manuscript. GB, FBi, MB, CT, FBe, MR, and GU wrote sections of the manuscript. All authors contributed to manuscript revision, read, and approved the submitted version.

Funding

The OBSERVANT study was supported by a grant (Fasc. 1M30) from the Italian Ministry of Health and Istituto Superiore di Sanità. The OBSERVANT II study was supported by the Italian Ministry of Health within the call Ricerca Finalizzata 2016 (code PE-2016-02364619).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships...
that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.991729/full#supplementary-material

References

1. Vahanian A, Beyersdorf A, Priftis K, Moller JH, Budde KP, Bax JJ, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. (2021) 42:561–632. doi: 10.1093/eurheartj/ehab985

2. Clavel MA, Magne J, Pibarot P. Low-gradient aortic stenosis. Eur Heart J. (2016) 37:2645–57. doi: 10.1093/eurheartj/ehw096

3. Tarantini G, Buja P, Scognamiglio R, Razzolini R, Gerosa G, Isabella G, et al. Aortic valve replacement in severe aortic stenosis with left ventricular dysfunction: determinants of cardiac mortality and ventricular function recovery. Eur J Cardiothorac Surg. (2003) 23:879–85. doi: 10.1016/s0145-5613(03)00575-x

4. Connolly HM, Oh JK, Schaff HV, Roger VL, Ossorio SL, Hodge DO, et al. Severe aortic stenosis with low transvalvular gradient and severe left ventricular dysfunction: results of aortic valve replacement in 52 patients. Circulation. (2000) 101:1940–6. doi: 10.1161/01.cir.101.16.1940

5. Perera JI, Laufer MS, Bashir M, Afridi I, Blackstone EH, Stewart WJ, et al. Survival after aortic valve replacement for severe aortic stenosis with low transvalvular gradients and severe left ventricular dysfunction. J Am Coll Cardiol. (2002) 39:1356–63. doi: 10.1016/s0735-1097(02)71579-x

6. Vaquette B. Valve replacement in patients with critical aortic stenosis and depressed left ventricular function: predictors of operative risk, left ventricular function recovery, and long term outcome. Heart. (2005) 91:1324–9. doi: 10.1136/hrt.2004.044099

7. Levy F, Laurent M, Monin JL, Mallet JM, Pasquet A, Le Tourneau T, et al. Aortic valve replacement for low-flow/low-gradient aortic stenosis. J Am Coll Cardiol. (2008) 51:1466–72. doi: 10.1016/j.jacc.2007.10.067

8. Tribouilloy C, Lévy F, Ruminar D, Guèret P, Petit-Eisenmann H, Baleyraud S, et al. Outcome after aortic valve replacement for low-flow/low-gradient aortic stenosis without contractile reserve on dobutamine stress echocardiography. J Am Coll Cardiol. (2009) 53:1865–73. doi: 10.1016/j.jacc.2009.02.026

9. Tarantini G, Covolo E, Razzolini R, Bilato C, Frigo AC, Napodano M, et al. Valve replacement for severe aortic stenosis with low transvalvular gradient and left ventricular ejection fraction exceeding 0.50. Ann Thorac Surg. (2011) 91:1808–15. doi: 10.1016/j.athoracsur.2011.02.057

10. Clavel MA, Webb JG, Rodés-Cabau J, Masson JB, Dumont E, De Larochellière R, et al. Comparison between transcatheter and surgical prosthetic valve implantation in patients with severe aortic stenosis and reduced left ventricular ejection fraction. Circulation. (2010) 122:1928–36. doi: 10.1161/CIRCULATIONAHA.109.928993

11. Weber M, Bruggemann E, Schueler R, Momcilovic D, Sinning J-M, Ghanem A, et al. Impact of left ventricular conduction defect with or without need for permanent right ventricular pacing on functional and clinical recovery after TAVR. Clin Res Cardiol. (2015) 104:964–74. doi: 10.1007/s00392-015-0865-9

12. Contorri F, Fineschi M, Iadanza A, Santoro A, Mandoli GE, Cameli M. How to deal with low-flow low-gradient aortic stenosis and reduced left ventricular ejection fraction: from literature review to tips for clinical practice. Heart Fail Rev. (2022) 27:697–709. doi: 10.1007/s10741-021-00990-0

13. Herrmann HC, Pibarot P, Huetter I, Gertz ZM, Stewart WJ, Kapadia S, et al. Predictors of mortality and outcomes of therapy in low-flow severe aortic stenosis: a Placement of Aortic Transcatheter Valves (PARTNER) trial analysis. Circulation. (2013) 127:2316–26. doi: 10.1161/CIRCULATIONAHA.112.012930

14. Lauten A, Figulla HR, Mollmann H, Holzhey D, Kotting J, Beckmann A, et al. TAVI for low-flow, low-gradient severe aortic stenosis with preserved or reduced ejection fraction: a subgroup analysis from the German Aortic Valve Registry (GARY). EuroIntervention. (2014) 10:850–9. doi: 10.4244/EIJ10F1A145

15. Elhamedi Y, Piazza N, Krame M, Deutsch M-A, Mazzitelli D, Lange R, et al. Clinical presentation and outcomes after transcatheter aortic valve implantation in patients with low flow/low gradient severe aortic stenosis. Catheter Cardiovasc Interv. (2014) 84:283–90. doi: 10.1002/cdi.25366

16. Ribeiro HB, Lerasik S, Gilarad M, Cavalcante JL, Makkar R, Herrmann HC, et al. Transcatheter aortic valve replacement in patients with low-flow, low-gradient aortic stenosis: the TOPAS-TAVI registry. J Am Coll Cardiol. (2018) 71:1297–308. doi: 10.1016/j.jacc.2018.01.054

17. Barbanti M, Tamburino C, D’Errigo P, Biancari F, Ranucci M, Rosato S, et al. Five-year outcomes of transmembranal transcatheter aortic valve replacement or surgical aortic valve replacement in a real world population. Circ Cardiovasc Interv. (2019) 12:e007825. doi: 10.1161/CIRCINTERVENTIONS.119.007825

18. Sceccareccia F, Tarantini G, Bedogni F, Berti S, Santoro G, Tamburino C, et al. OBSERVANT II: Observational Study of Effectiveness of transcatheter aortic valve implantation with new generation Devices for severe Aortic stenoSis Treatment. Study protocol]. G Ital Cardiol. (2017) 18:145–26. doi: 10.1714/2718.27731

19. Rosato S, Biancari F, D’Errigo P, Barbanti M, Tarantini G, Bedogni F, et al. One-year outcomes after surgical versus transcatheter aortic valve replacement with newer generation devices. J Clin Med. (2021) 10:3703. doi: 10.3390/jcm10163703

20. Costa G, D’Errigo P, Rosato S, Biancari F, Marcellusi A, Tarantini G, et al. One-year outcomes and trends over two eras of transcatheter aortic valve implantation in real-world practice. J Clin Med. (2022) 11:1164. doi: 10.3390/jcm11051164

21. Tamburino C, Barbanti M, D’Errigo P, Ranucci M, Onorati F, Covello RD, et al. 1-Year outcomes after transfemoral transcatheter or surgical aortic valve replacement: results from the Italian OBSERVANT study. J Am Coll Cardiol. (2015) 66:804–12. doi: 10.1016/j.jacc.2015.06.013

22. Rockwood K, Stadnyk K, MacKnight C, McDowell I, Herbet R, Hogan D. A brief clinical instrument to classify frailty in elderly people. Lancet. (1999) 353:205–6. doi: 10.1016/s0140-6736(98)04002-x

23. VARG-3 WRITING COMMITTEE, Généreux P, Piazza N, Aliu MC, Nazif T, Hahn RT, et al. Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. Eur Heart J. (2021) 42:1825–57. doi: 10.1093/eurheartj/ehab799

24. Arnold SV, Reynolds MR, Lei Y, Magnuosen EA, Kirtane AJ, Kodali SK, et al. Predictors of poor outcomes after transcatheter aortic valve replacement: results from the PARTNER trial. Circ Cardiovasc Interv. (2014) 7:707–16. doi: 10.1161/CIRCINTERVENTIONS.113.007477

25. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. (2016) 374:1689–20. doi: 10.1056/NEJMoa1514616

26. Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Søndergaard L, Mumtaz M, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med. (2017) 376:1321–31. doi: 10.1056/NEJMoa1700456

27. Lindman BR, Alexander KP, O’Gara PT, Afilalo J, Futility, benefit, and transcatheter aortic valve replacement. JACC Cardiovasc Interv. (2014) 7:707–16. doi: 10.1016/j.jcin.2014.01.167
28. Zusman O, Kornowski R, Witberg G, Lador A, Orvin K, Levi A, et al. Transcatheter aortic valve implantation futility risk model development and validation among treated patients with aortic stenosis. *Am J Cardiol.* (2017) 120:2241–6. doi: 10.1016/j.amjcard.2017.09.007

29. Geisler D, Rudzinski PN, Hasan W, Andreas M, Hasimbegovic E, Adlbrecht C, et al. Identifying patients without a survival benefit following transfemoral and transapical transcatheter aortic valve replacement. *J Clin Med.* (2021) 10:4911. doi: 10.3390/jcm10214911

30. Fraccaro C, Al-Lamee R, Tarantini G, Maisano F, Napodano M, Montorfano M, et al. Transcatheter aortic valve implantation in patients with severe left ventricular dysfunction: immediate and mid-term results, a multicenter study. *Circ Cardiovasc Interv.* (2012) 5:253–60. doi: 10.1161/CIRCINTERVENTIONS.111.964213

31. Regazzoli D, Chiarito M, Cannata F, Pagnesi M, Misra M, Zivello F, et al. Transcatheter Self-expandable valve implantation for aortic stenosis in small aortic annulus: the TAVI-SMALL registry. *JACC Cardiovasc Interv.* (2020) 13:196–206. doi: 10.1016/j.jcin.2019.08.041

32. Hase H, Yoshijima N, Yanagisawa R, Tanaka M, Tsiruta H, Shimizu H, et al. Transcatheter aortic valve replacement with Evolut R versus Sapien 3 in Japanese patients with a small aortic annulus: the OCEAN-TAVI registry. *Catheter Cardiovasc Interv.* (2021) 97:E875–86. doi: 10.1002/ccd.29259

33. Bleiziffer S, Rudolph TK. Prosthesis-patient mismatch after SAVR and TAVR. *Front Cardiovasc Med.* (2022) 9:761917. doi: 10.3389/fcvm.2022.761917

34. Ruel M, Al-Faleh H, Kulik A, Chan KL, Mesana TG, Burwash IG. Prosthesis-patient mismatch after aortic valve replacement predominantly affects patients with preexisting left ventricular dysfunction: effect on survival, freedom from heart failure, and left ventricular mass regression. *J Thorac Cardiovasc Surg.* (2006) 131:1036–44. doi: 10.1016/j.jtcv.2005.10.028

35. Mohby D, Dumesnil JG, Echahidi N, Mathieu P, Dagenais F, Voisine P, et al. Impact of prosthesis-patient mismatch on long-term survival after aortic valve replacement: influence of age, obesity, and left ventricular dysfunction. *J Am Coll Cardiol.* (2009) 53:39–47. doi: 10.1016/j.jacc.2008.09.022

36. Colli A, Besola L, Salizzoni S, Gregori D, Tarantini G, Agrifoglio M, et al. Does pre-existing aortic regurgitation protect from death in patients who develop paravalvular leak after TAVI? *Int J Cardiol.* (2017) 233:52–60. doi: 10.1016/j.ijcard.2017.02.005

37. Athappan G, Patwardhan E, Tuzcu EM, Svensson LG, Lemos PA, Fraccaro C, et al. Incidence, predictors, and outcomes of aortic regurgitation after transcatheter aortic valve replacement: meta-analysis and systematic review of literature. *J Am Coll Cardiol.* (2013) 61:1585–95. doi: 10.1016/j.jacc.2013.01.047

38. Ueyama H, Kuno T, Harrington M, Takagi H, Krishnamoorthy P, Sharma SK, et al. Impact of surgical and transcatheter aortic valve replacement in low-gradient aortic stenosis: a meta-analysis. *JACC Cardiovasc Interv.* (2021) 14:1481–92. doi: 10.1016/j.jcin.2021.04.038

39. Buchanan KD, Rogers T, Steinvil A, Koffman E, Xu L, Torguson R, et al. Role of contractile reserve as a predictor of mortality in low-flow, low-gradient severe aortic stenosis following transcatheter aortic valve replacement. *Catheter Cardiovasc Interv.* (2019) 93:707–12. doi: 10.1002/ccd.27914